NDAORALTABLET
Approved
Oct 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
CAPOZIDE 25/25 (captopril; hydrochlorothiazide) by Bristol Myers Squibb is clinical pharmacology mechanism of action the mechanism of action of captopril has not yet been fully elucidated. Approved for hypertension, diabetic nephropathy (proteinuria > 500 mg/day) in patients with type i insulin-dependent diabetes mellitus, retinopathy and 8 more indications. First approved in 1984.
Drug data last refreshed 22h ago
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action The mechanism of action of captopril has not yet been fully elucidated. Its beneficial effects in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. However, there is no consistent…
Worked on CAPOZIDE 25/25 at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.